Immunotherapy in Non-small Cell Lung Cancer Treatment

Cancer is the uncontrolled development of cells, a class of diseases that poses a health threat worldwide. The immune system serve as a formidable defense mechanism against illnesses, infections, and other diseases. Cancer can undermine the immune system. Therefore, immunotherapy emerges as a promising solution that utilize the immune system to combat cancer and overcome cancer immune evasion. Non-small Cell Lung Cancer (NSCLC) is the most prevalent and lethal form of lung cancer. A type of immunotherapy, Immune Checkpoint Inhibitors (ICI) is used to cure NSCLC and is introduced as a first line treatment option. Despite the improved survival rates for ICI, it is crucial to acknowledge the immune-related adverse events and side effects that persist when being treated. This review provides a thorough overview of NSCLC, its treatment, innovation,ongoing clinical trials and prospects. Current medical research has highlight the evolving landscape of immunotherapy in NSCLC treatment. To ensure more effective treatment outcome and accessability, it is important to have more study and research being conducted to discover individualized and combination treatments.